It very sad that the company not do deal with Lilly before gemzar went generic. Now it generic market many competitors to attack patents and harder to get oncologist to stay with Lilly brand .
after 3 year since announcement of DEP gemcitibine it time for SPL to say when study will start like other company keep SH informed.
IMO efficiency data would have to be amazing to get payers to switch from generic to patented premium DEP GEM product same issue with DEP- docetaxel. witj current market size around 300-400m I think development cost is not likely going to be covered. This is not the sort of small fish that big pharma want. Also oncology has moved in new directions for most part - CART ADC and IO. IMO This old drug with weak commercial prospects.
I will bet with you Antibotter that there is no Lilly license this year . Whoever is loser stop posting for 1 month. Are you ready to do that?
DEP-Gemcitabine, page-10
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
0.001(1.03%) |
Mkt cap ! $40.97M | |||
| Open | High | Low | Value | Volume |
| 9.7¢ | 9.9¢ | 9.7¢ | $44.76K | 455.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 824859 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 121525 | 5 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |